Skip to content

Sellas Life Sciences

US · SLS #2687 by market cap Listed 1970
13.66 -1.20 -8.08%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:58

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 19 in the most recent period (2026/Q3).
  • Total institutional ownership rose 0.3 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
37.62% +0.31pp
Institutions
237 +19
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund30.34%
Hedge Fund2.51%
Private Company2.30%
Public Company1.78%
Individual/Insider0.39%
Government Pension Fund0.31%
Insurance Company0.19%
Family Office/Trust0.19%
Other61.99%

Top holders as of 2026-09-30

BlackRock 8.01% · 16.18M sh
State Street Global Advisors 5.14% · 10.37M sh
Vanguard Capital Management, LLC 4.43% · 8.94M sh
Geode Capital Management, LLC 2.56% · 5.17M sh
Anson Group 2.23% · 4.50M sh
Edward Jones Trust Company 1.14% · 2.30M sh
Vanguard Portfolio Management, LLC 1.14% · 2.30M sh
Susquehanna International Group, LLP 1.02% · 2.05M sh
UBS Asset Management 0.87% · 1.76M sh
Northern Trust Global Investments 0.80% · 1.62M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 41 buys · 6 sells

NameRoleStake
Angelos Stergiou Chief Executive Officer 0.15%
John Burns Senior Vice President 0.07%
Dragan Cicic Senior VP & Chief Development Officer 0.06%
Katherine Kalin Independent Director 0.05%
Jane Wasman Independent Director 0.02%
Robert Van Nostrand Independent Director 0.02%
David Scheinberg Independent Director 0.01%
John Varian Independent Chairman of Board 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-06-15 Angelos Stergiou Chief Executive Officer Other Acquisition +1,065,000 --
2026-01-06 Robert Van Nostrand Independent Director Other Acquisition +50,000 --
2026-01-06 John Varian Independent Chairman of Board Other Acquisition +50,000 --
2026-01-06 David Scheinberg Independent Director Other Acquisition +50,000 --
2026-01-06 Jane Wasman Independent Director Other Acquisition +50,000 --
2026-01-06 Dragan Cicic Senior VP & Chief Development Officer Other Acquisition +300,000 --
2026-01-06 John Burns Senior Vice President Other Acquisition +300,000 --
2026-01-06 Katherine Kalin Independent Director Other Acquisition +50,000 --
2025-12-02 Dragan Cicic Senior VP & Chief Development Officer Other Disposition -63,800 $1.50
2025-12-02 Angelos Stergiou Chief Executive Officer Other Disposition -187,066 $1.50
2025-12-02 John Burns Senior Vice President Other Disposition -58,592 $1.50
2025-11-18 Katherine Kalin Independent Director Open Market Acquisition +63,400 $1.59
2025-06-11 Robert Van Nostrand Independent Director Open Market Acquisition +10,000 $1.48
2025-05-29 Jane Wasman Independent Director Open Market Acquisition +20,000 $1.69
2025-05-21 Katherine Kalin Independent Director Open Market Acquisition +20,000 $1.80
2025-01-09 Robert Van Nostrand Independent Director Other Acquisition +12,500 --
2025-01-09 Robert Van Nostrand Independent Director Other Derivative Acquisition +18,500 $0.95
2025-01-09 John Varian Independent Chairman of Board Other Acquisition +12,500 --
2025-01-09 John Varian Independent Chairman of Board Other Derivative Acquisition +18,500 $0.95
2025-01-09 David Scheinberg Independent Director Other Acquisition +12,500 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:58:45 · For reference only, not investment advice and not tailored to your situation.

Sellas Life Sciences discussion 0 comments

Add a comment